Meeting/Workshop Slides
On this page:
Medical Countermeasures Against Nuclear Threats: Decorporation Agents—September 17 – 18, 2007, Bethesda, MD
Meeting Agenda (PDF)
Development and Acquisition of High Priority Radionuclide Medical Countermeasures—HHS/BARDA Roles and Responsibilities. Dr. Joanna Prasher, Department of Health and Human Services, Washington, DC (PDF)
Development of Improved DTPA for Radionuclide Chelation: Transport Enhancers. Dr. Gita Shankar, SRI International, Menlo Park, CA (PDF)
Polonium-210 and Sulfhydryl Chelating Agents. Dr. H. Varsken Aposhian, University of Arizona, Tucson, AZ (PDF)
Use of Sypine® and Cuprimine®, FDA-Approved Therapeutics for Wilson’s Disease, as Oral Radioisotope Decorporation Agents. Dr. Barry Levinson, Aton Pharma, Inc., Princeton, NJ (PDF)
Desferrithiocin Analogue Actinide Decorporation Agents. Dr. Raymond Bergeron, University of Florida, Gainesville, FL (PDF)
Amphipathic Oral Chelators and Radionuclide Contamination. Dr. Scott Miller, University of Utah, Salt Lake City, UT (PDF)
Medical Countermeasures for Radiation Combined Injury: Radiation with Burn, Blast, Trauma, and/or Sepsis—March 26 – 27, 2007, Chevy Chase, MD
Meeting Agenda (PDF)
Meeting Report published June 2008 in Radiation Research (PDF)
Overview of Combined Injury: Radiation in Combination with Trauma, Infectious Disease or Chemical Exposure. Dr. Terry Pellmar, Armed Forces Radiobiology Research Institute, Bethesda, MD (PDF)
Combined Radiation Injuries after the Chernobyl Accident: Management, Outcome & Lessons Learned. Dr. Alla Shapiro, Food and Drug Administration, Silver Spring, MD (PDF)
Advancements on Understanding Key Questions of Radiation Combined Injuries. Dr. Zhongmin Zou, Institute of Combined Radiation Injury, Third Military Medical University, China (PDF)
Study on the Protection and Mechanism of Cervical Sympathetic Block (SB) on Combined Radiation and Burn Injury in Rats. Dr. Yongping Su, Institute of Combined Radiation Injury, Third Military Medical University, China (PDF)
Factors Affecting the Outcome of Sepsis. Dr. Peter Ward, University of Michigan Health Systems (PDF)
The Impact of Burn Injury on Inflammatory and Immunologic Functions: Clinical and Experimental Perspectives. Dr. Martin Schwacha, University of Alabama at Birmingham (PDF)
Current Concepts in the Triage with Early Management of Combined Injuries: Trauma/Burns and Accidental Exposure to Ionizing Radiation. Dr. Erwin F. Hirsch, Boston University Medical Center, Boston, MA (PDF)
Effects of Radiation and Traumatic Brain Injury on Hippocampal Neurogenesis. Dr. John Fike, University of California, San Francisco, CA PDF)
Radiation Effects: Research at FOI—Proteomic Studies of Radiation Response. Dr. Daniela Stricklin, Swedish Defense Research Agency (PDF)
Combined Injury in Radiation Threat Environments and Countermeasure Evaluations. Dr. G. David Ledney, Armed Forces Radiobiology Research Institute, Bethesda, MD (PDF)
Countermeasures for Radiation-Induced Skin Injury. Dr. Paul Okunieff, University of Rochester Medical Center, NY (PDF)
Potential New Pharmaceutical Agents for Accelerating Wound Healing and for the Prevention and Reduction of Scarring. Dr. Mark Ferguson, University of Manchester, England (Link to Renovo Web site)
Thrombin Peptide TP508, More Than Just a Tissue Repair Factor: Can Its Effects on Endothelial Dysfunction Offer Protection for Blast and Radiation Injury? Dr. Darryl Carney, University of Texas Medical Branch (PDF)
Cutaneus Radiation Syndrome and Radiation-Induced Multi-Organ-Involvement. Dr. Harald Dörr, Bundeswehr Institute of Radiobiology, Munich, Germany
Consensus Discussion Slides (PDF)
Predicting Individual Radiation Sensitivity: Current and Evolving Technologies—March 17 – 18, 2008, New York, NY
Meeting Agenda (PDF)
Overview. Dr. Richard Hatchett, NIAID, NIH, Bethesda, MD (PDF)
The Radiation Oncology-Nuclear Terrorism Perspective. Dr. Norman Coleman, NCI, Bethesda and ASPR, HHS (PDF)
Possible High-Throughput Screening Logistics. Dr. David Brenner, Columbia University, New York, NY (PDF)
Prediction of Normal Tissue Radiosensitivity from Polymorphisms in Candidate Genes. Dr. Nicolaj Andreassen, Aarhus University, Denmark (PDF)
International Consortium to Create a Biorepository/Databank for the Performance of Genome-wide SNP Association Studies. Dr. Barry Rosenstein, Mount Sinai School of Medicine, New York, NY (PDF)
Candidate and Whole Genome SNP Association Studies of Late Radiation Toxicity in Prostate Cancer Patients. Dr. Matthew Parliament, University of Alberta, Edmonton, Canada (PDF)
SNPs and Late Fibrosis. Dr. Jan Alsner, Aarhus University Hospital, Denmark (PDF)
Predicting Radiotherapy Induced Late Toxicity by Gene Expression Profiling. Dr. Peter Svensson, MIT, Cambridge, MA (PDF)
Multiple Genetic Variants Associated with Risk of Adverse Reactions following Radiotherapy in Cancer Patients: A Large-Scale Candidate Gene Approach. Dr. Takashi Imai, National Institute of Radiological Sciences, Chiba, Japan (PDF)
Extracting Meaningful Biomarkers from Gene Expression Data. Dr. Michael Bittner, TGen, Phoenix, AZ (PDF)
Systems Biology: Integrating Information for Better Predictions. Dr. Francis Cucinotta, NASA Johnson Space Center, Houston, TX (PDF)
Predicting Individual Radiation Sensitivity: Where Next? Dr. Bhadrasain Vikram, NCI, NIH, Bethesda
Where Next? Dr. Barry Rosenstein, Mount Sinai School of Medicine, New York, NY (PDF)
back to top